Nat. Volatiles & Essent. Oils, 2021; 8(6): 2055-2063

NVEO
Natural Volatiles &
Essential Oils

Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death

Yuldashev Soatboy Jiyanboyevich[1] , Dr. Imran Aslam[2] , Murodova Umida Ravshanovna[3] , Farmanova Gulhayo Azamatovna[4] , Jalilova Dildora Murodovna[5]

[1]Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan

[2]Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan

[3]Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan

[4]Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan

[5]Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan

Abstract:

A remarkable number of deaths in foetal cardiac disorders have been reduced as a result of significant gains in survival. Arrhythmias are most common issue that patients encounter. Expert societies have issued evidence-based recommendations for addressing the distinctive disputes and problems of dealing arrhythmias in patients with congenital cardiac ailment, as well as critical judgments for sudden death prevention. Continued progresses in hazard evaluation and technology are capable to develop the safety and efficacy of this rapidly growing patient population. This ventricular remodelling, like other forms of heart disease, unexpected death, ventricular tachycardia (VT) and ventricular fibrillation (VF). A large ventricular patch induces prolonged monomorphic reentrant VT, which can cause haemodynamic failure and abrupt cardiac death. Severe VT and VF treatment can be performed according to standard procedures. Chronic management includes heart failure therapies and healing therapy for the underlying congenital heart defect, but particular arrhythmia managing is best delivered by an experienced electrophysiologist who can accurately identify arrhythmia and its pathway, offer analytical stratification, govern the substrate, and control specialty electrical treatments like antitachycardia pacing and implantable cardiac defibrillation via an impedance monitor. Finally, electrophysiological analysis can assist the surgeon in determining if arrhythmia-neutralizing incisions should be included in the reparative surgery.

Keywords: Ventricular arrhythmias, sudden death, congenital heart disease, acute management, implantable cardioverter defibrillator (ICD)

Introduction

Majority of individuals with significant lesions did not survive to adulthood, congenital heart disease (CHD) was previously thought to be a paediatric condition. On the other hand, developments in initial detection and cardiac surgical treatment have moved the pressure of illness from paediatricians to adult doctors. As a result, elderly congenital heart disease (ACHD) individuals now outnumber juvenile patients by a large margin. (Teun et al, 2012) The global endurance of patients with congenital cardiac

disease have upgraded dramatically because of progress in modern medicine (CHD). Despite substantial advances in diagnosis, early treatment, and adult management, many sufferers continue to experience continuing problems for example arrhythmia, thrombosis, cardiac arrest, endocarditis, pulmonary hypertension or the necessity for operation. Furthermore, half of the cases are female, with the most of them being of births, necessitating obstetric treatment and specialised reproductive counselling. As a result, it's not unexpected that CHD-related healthcare utilisation has risen considerably in current years. Moreover, cardiology and other medicinal professions are now confronted with new obstacles, such as providing expert treatment and ideal, lifetime medical surveillance for patients. (Ntiloudi et al, 2016)

Ventricular arrhythmias are irregular heartbeats that begin in the ventricles, the lower chambers of the heart. These arrhythmias increase heart rate, preventing oxygen-rich blood to circulate the brain and body and possibly resulting in cardiac arrest. Ventricular arrhythmias are a key reason of disability and unexpected death in nearly all kinds of cardiac illness. The calculation of the danger of untimely death and appropriate prophylaxis are most important considerations in individuals with cardiac arrhythmias. In cases where physical cardiac disease or inherited arrhythmia disorders are present, an implanted cardioverter defibrillator (ICD) is measured. ICDs efficiently stop the majority of incidents of ventricular tachycardia or fibrillation in high-risk individuals who have never had a ventricular arrhythmia before, lowering total mortality. Antiarrhythmic medicines and catheter ablation are both successful in decreasing ICD shocks and symptomatic arrhythmias. (Roy et al, 2012) Every year, 50–100 due to sudden cardiac deaths occur per 100,000 people in Europe and North America. (Fishman et al, 2010) (Goldberger et al, 2011) Adults more than 35 years have prevalence of 1 per 1000 population, whereas those young than 35 years have an incidence of 1 per 100 000. Ventricular tachycardia and ventricular fibrillation is accountable for approximately half of these occurrences. Over the last two decades, the number of cases with pulseless electrical activity or asystole has risen for unknown reasons. (Teodorescu et al, 2010) Only about 5% of patients who have an out-of-hospital heart attack survive. (Fishman et al, 2010)

A suggested dynamics-based cataloguing of ventricular arrhythmias was developed based on these premises, describing how dynamic parameters at the cell, tissue, and entity sizes connect to arrhythmia threat at the organ level. The main clinically significant ventricular arrhythmias are divided into three groups, with main dynamic destabilisation encouraging arrhythmias being associated to according to this classification.

i. unbalanced Ca cycling
ii. lowered repolarization
iii. surplus repolarization

Each group details the significant exceptional and frequent experimental disorders, arrhythmia mechanism, cellular and tissue dynamic forces, and important dynamic elements that influence them, all of which can be used as prevention goals. (Weiss et al, 2015) For ages, cardiac arrhythmias is documented as a major consequence of heart disease. In general, cardiac arrhythmias are disorders in which the heart's electrical activity becomes excessively slow, too rapid, or too irregular. Speedy heart rhythms that lead to atrial or ventricular fibrillation, whereby the electrical action in atria and ventricles

goes turbulent is a noticeable cause of mortality and morbidity, predominantly sudden cardiac death in developed countries. (Qu & Weiss, 2015)

Arrhythmia prevention and therapy are critical in patient care in order to reduce morbidity and mortality from heart stroke, heart failure, and unexpected death. Early recognition and diagnosis of CHD, introduction of initial and less intrusive clinical procedures, and monitoring of cardiovascular hazard are all part of arrhythmia prevention. Stroke avoidance in atrial arrhythmias, rate management, arrhythmia reduction with antiarrhythmic medications, and, preferably, medicinal remedy with catheter ablation are all ways to avoid problems. Checking and handling of hemodynamic issues and systemic ventricular purpose, in addition to clinical threat for patients are all part of preventing sudden cardiac death. (Wasmer et al., 2021)

Therapies for ventricular arrhythmias

Antiarrhythmic medicines, cardiac implantable devices such as ICDs, and catheter and surgical ablation focused at arrhythmia cause are all direct therapy options for ventricular arrhythmias. When presented with VT in a patient suffering from CHD in an emergency situation, normal guideline-based care is used. Sustained ventricular arrhythmias should be treated as quickly as possible, especially in patients with complicated CHD. Electrical cardioversion or defibrillation is chosen therapeutic choice in most cases. It's important to remember that the location of the external defibrillation pad is adjusted with respect to position of heart in patients with CHD. The pads are situated at minimum 8 cm away from the originator in patients who have intracardiac devices. In the unusual sufferers with consistent haemodynamics and a stood arrhythmia lacking considerable ventricular mark or may be deformation, drug management for cardioversion of prolonged VT may be considered. The amount and seriousness of ventricular alteration, the danger of proarrhythmia and heart arrest, and drug-specific lasting adverse effects are all factors that limit long-term pharmacological dealing of ventricular arrhythmias. Sotalol and amiodarone as particular medicines and beta-blockers as drug treatment are effective (Khairy and Paul 2016). An EP study may be necessary in certain CHD individuals, mainly with a surgical ventricular wound, to accurately differentiate supra-ventricular arrhythmias.

Catheter ablation of VT with CHD can likewise be used as an alternate to drug treatment in patients with an ICD and indicative VT, and it might be suitable for non-sustained VT or relatively well suitable VT when aiming anatomical isthmuses or for common ectopy in patients with acute severe ventricular function. In people with slow but prolonged tachycardias, ablation is performed significantly less commonly to solve the haemodynamic risk.

SCD occurs at a rate of 0.9 per 1000 patient yearly in corrected CHD, which are 25-100 folds greater than in the common population. (Michael et al, 1998) Interrogation of ICDs implanted for both prime and secondary avoidance in patients with corrected **Tetralogy of Fallot** (TOF) and **Therapeutic Goods Administration** (TGA) has revealed that rapid and monomorphic VT accounts for more than 80% of all ventricular arrhythmias in mended TOF patients and roughly 50% in TGA patients (Khairy et al, 2008).

Materials and Methods

A 14-year-old child was hospitalised to an EP unit with recurring monomorphic VT. He was born with double-outlets of ventricle on right side and a flexible and dynamic ventricular septal defect (VSD). When he was 3 years old, he had pulmonary artery and atrial septostomy banding, which was accompanied by Rastelli-type adjustment comprising sub aortic conal resection, patch closing of VSD with formation of interior hemi-tube forming continuous ventricular flow of left side out with aorta, and exterior right ventricle to pulmonary artery channel (instructed by irregular left frontal downward artery initiating starting right coronary artery and overpassing anterior right ventricle). This duct had to be surgically expanded twice before being surgically corrected. Despite antiarrhythmic pharmaceutical therapy with sotalol and amiodarone, monomorphic unrelenting VT had recurred several times since the age of 7 (fig. 1, left panel), necessitating electrical cardioversions.

Figure 1



Figure1: The left panel depicts a medical VT along left bundle-branch block, left-hand alignment layout, along with precordial change in V5 that is well-suited with right ventricle free wall departure. With an anteroposterior (AP) outlook on topmost and a left crosswise view underneath, the central screen displays fluroscopic stills with catheter in pulmonary artery (PA) on right side through inferior vena cava to atrium and then in ventricle of right side and a proceeded catheter in the dextro-posed aorta and aortic origin. White arrows specify hardened RV to PA duct, and a dash line demonstrates its connection with the RV. Right section depicts an electro-anatomical initiation map of RV, with an AP viewpoint on top and a left lateral view on right side. An orange colour directs primary activation, while a purple hue indicates late initiation. The septal RV is first activated, and then the RV free wall, and lastly area near

superior tricuspid annulus. Ablation wounds are delivered in a "linear" continuous pattern from the conduit's basis (grey zone presenting scar and 3 blue dots), in addition to at fractionated and late prospective locations.

An electroanatomic voltage plot (fig. 2, right section) and activation plot (fig. 1, right section) of ventricle (RV) were produced in sinus pulse, verifying less voltage region through postponed activation in septal drainage area, coherent with VSD ventricular (left) discharge patch, in addition also comparable area in frontal outflow, persistent with channel's basis (fig. 1, middle panel: duct directed via white arrows on fluoroscopic visions).

Figure 2



Figure 2: ECG of VT2, which was stimulated after RV wall free lined disease was formed, is shown on the left panel, with anatomy denoting septal superior escape valve (QR in V1, change V3). In the central section, the observation at septal intersection of the RV summit with conduits during this VT is depicted (white arrow in right panel). Ablation catheter implanted at septal RV summit meeting, as well as hints II, III, V1, and V6, display strong diastolic fractionation potentials (DP), which are larger in intensity and sharp in the ablation catheter's proximal electrodes (Abl p). There are additional RV electrograms (VD1–4) with obviously systolic scheduling. Right section displays an electro-anatomic sinus rhythm voltage

map, purple colour identifying bipolar endocardial voltage higher than 1.5 mV and other colours stating lesser voltage. Voltage map is evidently centred around the conduit's base, as well as in the septal superior and peritricuspid regions, such as the zone wherever DPs were noted during VT2.

In experimental VT, there was left bundle-branch blocked as well as a leftward axis arrangement, as well as a precordial changeover showing right ventricular unrestricted wall departure. A series of connecting radiofrequency wounds reaching from the inferior border of the frontal sector to the anterior boundary of tricuspid annulus were created on the anterior wall of right ventricle (fig. 1, left and right sections). More wounds occurred in the slender region of normal-voltage tissue among both the septal and anterior wound regions. Inducibility analysis established that the medical VT could not be prompted, but a continuous monomorphic VT (VT2) with an lower axis, QR morphology in V1 and a transition in V3, implying a septal superior departure, likely closer to septal left ventricular discharge zone patch (figs 1 and 2, right panels). Due to the vicinity of the His bundle potential, diastolic abilities were documented on right ventricular side of this area during continuous VT (fig. 2, central section), and radiofrequency lesions were gently supplied to this area in sinus rhythm. (fig. 3).

Figure 3



There are aberrant delayed aptitudes in sinus rhythm. There are 3 alternative approaches to display late potentials in fractions (beyond terminal surface in ECG QRS, LP). Observe the His bundle deviation on the left side of trace. A putative arrhythmogenic isthmus can be seen in these electrograms.

Results

Regardless of the fact that a VT with a similar morphology to 2nd VT maintained inducible, no more ablation challenges in this area or on the matching left were performed due to closeness to atrioventricular transmission system and medical VT's noninducibility. After the duct was by-operation upgraded for haemodynamically important stenosis and solo compartment ICD was inserted a few weeks later, there were no difficulties or arrhythmia recurrence. Despite having an ICD implant during initial check-up, he has been fine for the past three years deprived of any antiarrhythmic treatment or any ICD intrusion.

This case shows several important issues about ventricular arrhythmias in individual with severe CHD. He has surgical marks of the implanted tube, along with the VSD-left ventricular drainage cover with low voltage tissue superseding zone, were anatomical barriers. The medical VT consistent with a right ventricular free wall departure was most likely caused by a macro-reentrant route about the tricuspid annulus or conduit insertion location. The right free wall laceration, as shown in the diagrams, was produced to prevent electrical stimulation from maintaining any or two of the mentioned re-entry circuits, preventing them from being caused again. The second VT, on the other hand, had mid-diastolic potentials at the septal VSD-left ventricular outflow reinforcement region, as well as a surface ECG representing a septal exit, but cannot be abated. The critical channel that kept this VT continuing was most likely deep within the fibrous tissue towards the septal patch's board, adjacent to the His bundle, and unaffected by radiofrequency inserted tissue warming from the right side. Despite the fact that it was non-clinical, the residual VT was inducible, necessitating the use of an ICD. There has been no ICD intervention or VT in the last three years lacking the use of antiarrhythmic medicines. Using proper therapies can lessen the number of unexpected death due to cardiac diseases.

Discussion

Patients' sufferings with ventricular arrhythmias along with congenital heart disease (CHD) were unable to survive in past decades but now due to advancement in the technology and medical fields their survival is made possible. Medical and both surgical management technics are used effectively to control irregular heartbeats that begin in the ventricles and ultimately lowering risks of sudden death. Santangeli et al, showed that short-term motorized hemodynamic support the in patient's presentation and hemodynamic parameters may be effective in high risk cases. In critical patients who are suitable for these surgical treatments, modern remedies for pump failure or refractory VAs, such as heart transfer and sturdy mechanical circulatory support is necessary. (Santangeli et al., 2017)

In the uncommon patient with steady haemodynamics and endured arrhythmia without considerable ventricular mark or distortion, drug management for cardioversion of prolonged VT may be considered. The degree and strictness of ventricular redesigning, the danger of proarrhythmia and heart arrest, and drug-specific lasting adverse effects all limit long-term pharmacological handling of ventricular arrhythmias. Because there isn't much data in this patient group, amiodarone and sotalol have been used as particular drugs, with beta-blockers used as adjuvant therapy when likely. Schleifer et al., research also concluded that patients with ventricular arrhythmias have mechanical heart disease, pharmacologic usage for ventricular arrhythmias is confined to amiodarone, D-,L-sotalol, and dofetilide in combination with defibrillator implantation. While amiodarone reduces arrhythmias better than other

drugs, it has long-term extracardiac side effects that can cause severe morbidity. If there are no contraindications, a trial of sotalol is reasonable, although it should be noted that over 20% of patients must stop taking it due to side effects. For the majority of patients, beta blockers are their first line of defence. Antiarrhythmic drugs that are more effective and have less long-term toxicity should be the focus of future research. (Schleifer et al., 2015)

Conclusion

In individuals with CHD, ventricular arrhythmias are a main source of sickness and death. The majority of people with VT can be effectively managed with proper diagnosis and treatment. Though prognostic assistances have not yet been revealed, recent diagnostic electrophysiology expertise can lead to individual needs identification of present and probable arrhythmogenic tissue isthmuses, letting in many patients' their neutralization by catheter ablation, with subsequent progresses in arrhythmia overcome signs and death rate.

Conflict of interest

No conflict of interest.

Acknowledgments

References

1. Teun van der Bom; Berto J. Bouma; Folkert J. Meijboom; Aeilko H. Zwinderman; Barbara J.M. Mulder (2012). The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. , 164(4), –. doi:10.1016/j.ahj.2012.07.023
2. Ntiloudi, Despoina; Giannakoulas, George; Parcharidou, Despoina; Panagiotidis, Theofilos; Gatzoulis, Michael; Karvounis, Haralambos (2016). Adult congenital heart disease: A paradigm of epidemiological change. International Journal of Cardiology, (), S0167527316309524–. doi:10.1016/j.ijcard.2016.05.046
3. Roy M John; Usha B Tedrow; Bruce A Koplan; Christine M Albert; Laurence M Epstein; Michael O Sweeney; Amy Leigh Miller; Gregory F Michaud; William G Stevenson (2012). Ventricular arrhythmias and sudden cardiac death. , 380(9852), –. doi:10.1016/s0140-6736(12)61413-5
4. Fishman, G. I.; Chugh, S. S.; DiMarco, J. P.; Albert, C. M.; Anderson, M. E.; Bonow, R. O.; Buxton, A. E.; Chen, P.-S.; Estes, M.; Jouven, X.; Kwong, R.; Lathrop, D. A.; Mascette, A. M.; Nerbonne, J. M.; O'Rourke, B.; Page, R. L.; Roden, D. M.; Rosenbaum, D. S.; Sotoodehnia, N.; Trayanova, N. A.; Zheng, Z.-J. (2010). Sudden Cardiac Death Prediction and Prevention: Report From a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation, 122(22), 2335–2348. doi:10.1161/circulationaha.110.976092
5. Goldberger, J. J.; Buxton, A. E.; Cain, M.; Costantini, O.; Exner, D. V.; Knight, B. P.; Lloyd-Jones, D.; Kadish, A. H.; Lee, B.; Moss, A.; Myerburg, R.; Olgin, J.; Passman, R.; Rosenbaum, D.; Stevenson, W.; Zareba, W.; Zipes, D. P. (2011). Risk Stratification for Arrhythmic Sudden Cardiac Death: Identifying the Roadblocks. Circulation, 123(21), 2423–2430. doi:10.1161/circulationaha.110.959734

6. Teodorescu, C.; Reinier, K.; Dervan, C.; Uy-Evanado, A.; Samara, M.; Mariani, R.; Gunson, K.; Jui, J.; Chugh, S. S. (2010). Factors Associated With Pulseless Electric Activity Versus Ventricular Fibrillation: The Oregon Sudden Unexpected Death Study. Circulation, 122(21), 2116–2122. doi:10.1161/circulationaha.110.966333
7. Weiss, James N.; Garfinkel, Alan; Karagueuzian, Hrayr S.; Nguyen, Thao P.; Olcese, Riccardo; Chen, Peng-Sheng; Qu, Zhilin (2015). Perspective: A dynamics-based classification of ventricular arrhythmias. Journal of Molecular and Cellular Cardiology, 82(), 136–152. doi:10.1016/j.yjmcc.2015.02.017
8. Qu, Z., & Weiss, J. (2015). Mechanisms of Ventricular Arrhythmias: From Molecular Fluctuations to Electrical Turbulence. Annual Review Of Physiology, 77(1), 29-55. https://doi.org/10.1146/annurev-physiol-021014-071622
9. Wasmer, K., Eckardt, L., Baumgartner, H., & Köbe, J. (2021). Therapy of supraventricular and ventricular arrhythmias in adults with congenital heart disease—narrative review. Cardiovascular Diagnosis And Therapy, 11(2), 550-562. https://doi.org/10.21037/cdt-20-634
10. Michael J Silka; Bruce G Hardy; Victor D Menashe; Cynthia D Morris (1998). A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. , 32(1), 245–251. doi:10.1016/s0735-1097(98)00187-9
11. Khairy, Paul (2016). Ventricular arrhythmias and sudden cardiac death in adults with congenital heart disease. Heart, 102(21), 1703–1709. doi:10.1136/heartjnl-2015-309069
12. Khairy, P.; Harris, L.; Landzberg, M. J.; Viswanathan, S.; Barlow, A.; Gatzoulis, M. A.; Fernandes, S. M.; Beauchesne, L.; Therrien, J.; Chetaille, P.; Gordon, E.; Vonder Muhll, I.; Cecchin, F. (2008). Implantable Cardioverter-Defibrillators in Tetralogy of Fallot. Circulation, 117(3), 363–370. doi:10.1161/CIRCULATIONAHA.107.726372
13. Ventricular arrhythmias in congenital heart disease: how can the electrophysiologist help?. (2017), 20(02), 27-35. https://doi.org/10.4414/cvm.2017.00459
14. Santangeli, P., Rame, J., Birati, E., & Marchlinski, F. (2017). Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. Journal Of The American College Of Cardiology, 69(14), 1842-1860. https://doi.org/10.1016/j.jacc.2017.01.047
15. Schleifer, J., Sorajja, D., & Shen, W. (2015). Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opinion On Pharmacotherapy, 16(17), 2637-2651. https://doi.org/10.1517/14656566.2015.1100170